Johan Georg Harmenberg

OncoReg's business concept is to provide novel sensitizers that enhance the sensitivity of tumors to other treatments. OncoReg has found that a combination of radiotherapy and its sensitizer can make therapy resistant tumors responsive to radiotherapy. The firm's lead compound, in combination with radiotherapy, leads to total regression of therapy resistant tumors in mice.

Part of Roche Holding AG, Roche AB is a biotechnology company founded in 1896. The private company is based in Solna, Sweden and creates innovative treatments to help millions of patients worldwide. Roche actively seeks partnerships with healthcare providers, academia, patient associations, organizations, external companies, and startups to identify needs that form the basis for collaborations. Roche is one of the world's largest research-based biotechnology companies, focusing on advancing science to improve people's lives. The Swedish company develops both drugs and diagnostics and has great respect for the multiple perspectives required to create tomorrow's healthcare.

Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden.

Part of KarSar Fastigheter AB, Sarak Fastigheter AB is a private company that owns and manages real and personal properties. The company is based in Stockholm, Sweden.

Glionova AB develops cancer treatment drugs. The firm is a drug discovery and development company. It offers GLN-1001 product. The company was founded by Lars G. J. Hammarström and Patrik Ernfors in 2014 and is headquartered in Stockholm, Sweden.

KarSar Fastigheter AB provides security brokerage and real estate services. The private company is based in Stockholm, Sweden and has subsidiaries in Sweden.

Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway.